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Abstract: Methods for the generation of nanoparticles encapsulated within 
cage proteins, such as ferritins, provide particles with low polydispersities due 
to size constraint by the cage. The proteins can provide enhanced water 
solubility to enable biological applications and affinity and identification tags to 
facilitate delivery or the assembly of advanced materials. Many effective 
methods have been developed, however, they are often impeded by cage 
protein instability in the presence of reagents or conditions for formation of the 
nanoparticles. Although the stability of ferritin cage quaternary structure can 
be enhanced, application of ferritins to materials science remains limited by 
unpredictable behaviour. Recently, we reported a medium throughput 
technique to directly detect the ferritin cage state.  Herein, we expand this 
strategy to screen conditions commonly used for the formation of gold 
nanoparticles. Not only do we report nanoparticle formation conditions that 
permit ferritin stability, we establish a general screening strategy based on 
protein cage stability that could be applied to other protein cages or for the 
generation of other types of particles. 
 
1. Introduction 
 
As a close symbiosis between protein and material science research 
matures,1,2 it is realized that the functionalization of nanomaterials with bio-
  
molecules not only enhances the properties of the materials, but can also 
assist their development for biological applications.3,4  Toward these ends, 
nanocage proteins,5 because of their hollow cavities with defined size and 
shape, have been used as size-constrained reactors to afford nanoparticles 
with narrow polydispersities. 6 , 7 , 8 , 9   In addition, they provide the resulting 
encapsulated particles with enhanced solubility, protect the particles from 
aggregating, and enable the further manipulation of the particles through 
bioconjugate and fusion strategies.10,11 
While other nanocages, such as cowpea chlorotic mottle virus6 or lumazine 
synthase,12 have been used for nanoparticle formation, the well-characterised 
structure, unique size and symmetry, and native mineralisation activity of 
ferritins make them especially ideal for these applications, and, to date, 
gold, 13 , 14  silver, 15  copper, 16  cadmium, 17  palladium 18  and platinum 19 
nanoparticles have been generated inside proteins of the ferritin family. Most 
ferritins assemble into nano-scale, spherical nanocages which act to maintain 
cellular iron homeostasis,20, 21,22,23,24  and the ferritin superfamily has provided 
excellent models for the study of protein quaternary structure25,26,27,28, 29,30 due 
to their relativity simple four-helix bundle-based monomer structures. Much 
ferritin-based materials research focuses on the mammalian horse spleen 
ferritin,2,13,31 , 32  specifically, the non-catalytically active Light Chain (L-chain 
HsFn). This ferritin is a maxi-ferritin, assembling into a protein cage made up 
of twenty-four monomers, possessing octahedral symmetry, and having cavity 
and outer diameters of 9 and 11 nm, respectively.  
Previously, we published a method for the generation of gold nanoparticles, 
which have been shown to be useful as catalysts, as contrast enhancing 
optical sensors and for medical diagnosis,33 inside unmodified HsFn using a 
two-step reduction strategy (Figure 1B and Table S1).13 The first step in the 
method involves the loading of gold ions into the ferritin cavity. Because the 
diffusion is slow, the solution can be rapidly desalted to remove gold external 
to the protein, a step that prevents gold precipitation on the outside of the 
cage.11 Then the internalized gold is clustered with a fast reducing agent, 
NaBH4, trapping it inside the nanocage. More gold feedstock is added, and 
the reaction mixture is then treated with a reducing agent, ascorbate, that 
requires a nucleating seed, resulting in slow growth of the nanocluster into a 
particle restricted to the size of the ferritin inner cavity. This method generates 
ferritin-encapsulated gold nanoparticles with extremely narrow polydispersities. 
However, follow-on attempts to establish this method as a general technique 
have been met with some difficulties. 
As a first attempt to expand our methodology to other ferritins, we targeted 
the E. coli mini-ferritin, DNA binding protein from starved cells (Dps),34,35 
because, as a 12-meric, tetrahedral cage protein with a 9 nm outer diameter 
and 4.5 nm diameter cavity,36,37 it should template gold nanoparticles of a size 
distinct from those we previously produced in the mammalian maxi-ferritin and 
it is expected that these smaller particles will have modified properties.33,38,39 
However, these attempts proved challenging due to both protein aggregation 
(see Figures 1C-top and S6B) and the protracted two day procedure, the 
length of which inhibits expeditious optimization. Therefore, we thought that 
the development of a strategy to rapidly and directly screen nanoparticle 
formation conditions with respect to protein cage stability would support the 
optimization process. 
  
Previously, we reported an assay that allows for the robust and selective 
detection of protein cage assembly in complex conditions, such as cellular 
lysates,40, 41 and we have recently expanded it to the screening of protein 
libraries in living cells.42 This assay was built upon work developed by the 
Tsien43, 44 and Schepartz45,46 labs and employs the bisarsinical probe, FlAsH, 
that fluoresces once its two ethanedithiol (EDT) ligands are replaced by four 
sulphur atoms projected from cysteine residues engineered in an ideal relative 
geometry across a protein-protein interface. To detect Dps mini-ferritin cages 
over other oligomerization states, we designed cage-specific FlAsH binding 
sites as pairs of cysteines fused to the Dps monomer C-terminus by a small 
peptide spacer (ProAlaGly) resulting in the protein, DpsPAGCC. Importantly, 
this method detects the cage over other states, including aggregate, and we 
have described its application in medium throughput format with 96-well 
plates to probe the stability of DpsPAGCC while scanning various pH and 
denaturation conditions simultaneously.40,41  
Herein, we present the evolution of this medium throughput, protein cage 
stability assay, to screen conditions typically used for the generation of gold 
nanoparticles.13 Because of the generality of the strategy’s design, it is 
thought that, in principle, it could be easily ported to other protein cages and 
conditions for the generation of other types of nanoparticles. 
 
  
 
Figure 1. (A) The medium throughput assay41 employs the fluorophore 
FlAsH43 and an optimized, cage-specific binding site to directly detect the 
cage state in ferritin proteins. (B) A two step reduction strategy13 was used to 
generate gold nanoparticles inside horse spleen maxi-ferritin protein cages.  
These original conditions were optimized to favour stable Dps mini-ferritin 
protein cages through the medium throughput assay described herein.   (C) 
Relative maximal absorbance for size exclusion chromatographic analysis of 
Dps stability and gold association (top) after exposure to nanoparticle 
generation conditions originally developed for horse spleen ferritin,13 and 
(bottom) after exposure to nanoparticle generation conditions optimised for 
Dps through the medium throughput screen for protein cage stability 
described herein.  The samples were monitored at 280 nm (dark bars) to 
observe protein and at 530 nm (light bars) to monitor gold, and the cage state 
is highlighted (red bars) Experimental details and conditions are provided and 
compared below in Table S1. 
  
 
2. Results and Discussion 
 
At the initiation of this project, we determined the effect the conditions we 
previously used for the generation of gold nanoparticles inside HsFn13 have 
on the quaternary structure of Dps. While expressed and purified Dps (see 
below and supporting information for full experimental details and 
characterization data) typically shows a major peak corresponding to intact 
protein nanocage when subjected to size exclusion chromatography (SEC) 
analysis (Fig. S6A), Dps exposed to the original nanoparticle formation 
conditions, resulted in primarily the formation of large protein (280 nm) 
aggregates with associated gold (520nm) (Figures 1C-top and S6B) indicating 
that the conditions that worked well for HsFn cause cage instability and 
disassembly in Dps.  
Traditionally, optimization of these conditions would be conducted through 
trial and error, which is a time- and resource-consuming process. Instead, we 
applied our previously published, medium throughput, 96-well format 
technique for the detection of mini-ferritin quaternary structure (see above). 
40,41  This techniques relies on detection of key protein-protein interactions, 
that are diagnostic of the assembled cage state, through the engineering of 
assembly-dependent binding sites for the reagent FlAsH for which binding is 
required to generate a fluorescent signal (Figure 1A).  Thus, increased signal 
correlates to an increase in population of the cage state. This technique is 
robust and has been applied to a 96-well plate format.  In this case, Dps was 
engineered to present these binding sites, resulting in the protein  
DpsPAGCC.  The goal of this research is to probe the cage-state stability of 
DpsPAGCC using the 96-well plate assay in conditions commonly used for 
the generation of gold nanoparticles (Figure 2-lower right) for the purpose of 
shifting the aggregate to the cage population of Dps from the ratio observed 
in our initial “cage-destabilizing” conditions (Figure 1C-top) to conditions that 
favour the cage (Figure 1C-bottom). 
Expressed and purified DpsPAGCC (see below and supporting information 
for full experimental details and characterization data) was subjected to 
varying concentrations of reagents which are commonly used for the 
generation of gold nanoparticles inside ferritins (HAuCl4, NaBH4, NaCNBH3, 
trisodium citrate, ascorbic acid)13,14 (Figure 2). Moreover, to determine if any 
observed instability was due to pH changes caused by the reagents, these 
conditions were screened both in unbuffered and buffered (100 mM Tris.HCl, 
100 mM NaCl, 1 mM EDTA, pH 7.8) solution. It was felt this information, albeit 
limited, could help shed some preliminary light on mechanism and direct 
future optimization while maintaining the spirit of a rapid assay with advanced 
throughput.  These conditions were screened in 96-well format in order to 
increase throughput and ensure reproducible comparison of data (Figure 2-
bottom right).  (Note:  To aid comparison, the initial “cage-destabilizing 
conditions used for Figure 1C-top are highlighted with black arrows in Figure 2 
and the optimized conditions used for Figure 1C-bottom are highlighted with 
red arrows.)  
The protein cage state of the mini-ferritin, as detected by the assay, was 
observed to be remarkably sensitive to the various conditions. Sodium 
cyanoborohydride and trisodium citrate conditions maintained stable protein 
  
nanocages across a wide range of concentrations with citrate demonstrating a 
slight stabilizing effect in unbuffered water. Ascorbic acid induced 
destabilization only at high concentration in buffer, but an effect on stability 
was extremely pronounced when not buffered. Interestingly, the cage state is 
quite sensitive to chloroauric acid, the gold source, but buffered conditions 
can extend the stability through a window of concentrations that does provide 
some flexibility. Interestingly, sodium borohydride, the reductant we initially 
used successfully with HsFn, destabilizes the mini-ferritin cage even in 
buffered conditions although, curiously, it appears to have a stabilizing effect 
at low concentrations in unbuffered water. The comparison between sodium 
borohydride and sodium cyanoborohydride is striking with an almost complete 
loss of structure with borohydride but stability across the concentration range 
with cyanoborohydride. Along with confirming the observation that the 
conditions that had been successful with HsFn caused major cage 
destabilization in Dps (Figure 1C-top), the screen also suggests a way 
forward, thereby emphasizing the utility and power of the strategy. 
Because the assay allowed the screening of multiple conditions 
simultaneously, we were able to generate sufficient information to make a 
multi-step optimization where we decreased the concentration of the gold 
solution to avoid local concentration effects, swapped the first reductant from 
sodium borohydride to sodium cyanoborohydride, and buffered all solutions 
using Tris. Convincingly, chromatographic analysis of Dps subjected to these 
new conditions demonstrated much less protein aggregation, and intact cages 
(280 nm) with associated gold (530 nm) made up the major population (Fig. 
1C-bottom and Fig. S6C). Thus, these results suggested that the optimized 
conditions were more compatible with stability of the protein cage and that the 
screening method was capable in identifying these conditions. 
It should be noted that this research is meant to establish a proof of 
principle to expand the medium throughput protein stability screen in novel 
directions and to demonstrate that it can be used to optimize conditions for 
the generation of nanoparticles inside protein cages.  While this goal has 
been achieved as evidenced by the data presented in this report, the 
conditions should in no way be considered conclusive.  Although the stability 
of the mini-protein has been greatly improved, further optimizations could be 
imagined and it would be expected that screening additional buffers, a wider 
range of pH or other gold sources could prove beneficial.   
 
  
 
 
Figure 2. Medium throughput protein stability screen of conditions for the 
generation of gold nanoparticles encapsulated within the mini-ferritin protein 
cage, DpsPAGCC. An assay was used that correlates fluorescence with the 
formation of key 3-fold symmetric protein-protein interactions in the mini-
ferritin in the presence of (top left) chloroauric acid (top right), sodium 
cyanoborohydride (middle left), sodium borohydride (middle right), trisodium 
citrate (bottom left), and ascorbic acid in both buffer (dark grey) and 
unbuffered (light grey) conditions. A schematic of a 96-well plate (Bottom 
right) with greyscale corresponding to average fluorescence intensity used in 
the bar graphs is presented. The data is normalised to DpsPAGCC in buffer 
with no added reagents (white bar). All data is averaged from 3 replicates. 
Arrows indicate conditions used for Figure 1C (black –conditions applied to 
DpsPACC from Fan et al. (2010)13 originally used for the generation of gold 
nanoparticles inside horse spleen ferritin (HsFn), Red – conditions optimized 
through this screen) and the schematized protein represents DpSPAGCC 
where the circles indicate the FlAsH binding site (black-Pro, dark grey-Ala, 
  
light grey-Gly, red-Cys).  See Supporting Information for comparison of 
conditions.  Error bars are S.D. 
 
4. Conclusions 
 
In this report, we have described an application of our medium throughput 
assay for the cage state of ferritin proteins. This method is based on the direct 
detection of the formation of designed FlAsH binding sites at symmetry-
related protein-protein interfaces.41  We used the technique to screen 
conditions for the formation of gold nanoparticles inside the mini-ferritin, Dps, 
and to determine if they are compatible with protein stability. While providing 
initial optimization for the type of nanoparticles of our immediate interest (gold 
nanoparticles) using our specific protein cage (a mini-ferritin), it further 
demonstrates the flexibility and practical utility of our protein cage stability 
assay which we are applying to the high throughput screening of protein 
libraries42 and to understand the fundamentals of protein assembly. More 
generally, this strategy could be very easily and directly expanded to screen a 
wider range of conditions, conditions for the generation of other types of 
nanoparticles, or conditions that are optimized for other protein cages. 
 
5. Experimental Details  
 
The supporting information contains SDS-PAGE and sequencing data 
from the purification of Dps and DpsPAGCC, SEC of purified DpsPAGCC, 
sequences of transfer primers, SEC chromatograms of the data used to 
generate Figure 1C, and comparisons of initial and optimized nanoparticle 
formation conditions. 
 
5.1 Cloning and expression of Dps and DpsPAGCC  
 
The gene for Dps in the plasmid pET-32b was expressed and purified 
as previously described.47 In short, the vector containing the gene coding for 
wild type Dps (see Fig. S5 for full sequence) was electroporated into BL21 
E.coli cells and plated on LB plates (50 μl/ml carbenicillin). Selected colonies 
were then grown in LB (5 ml, 37 °C, overnight) as a pre-culture which was 
later added to LB (500 ml) and grown (37 °C) until an O.D600 of 0.6 was 
reached. Protein expression was then induced by the addition of IPTG (final 
concentration 400 mM) and the cultures were further incubated (3 h, 30 °C). 
The cells were isolated by centrifugation (10,000 rpm, 20 min, 4 °C). The cell 
pellet was resuspended with lysis buffer (50 mM NaH2PO4, 300 mM NaCl, 40 
mM Imidazole, pH 8) and sonicated (15 min with 10 s on/off pulses, Sonics 
Vibra Cell). The protein solutions were clarified by centrifugation (10,000 rpm, 
20 min, 4 °C) and then filtered (Pall, 0.2 μm). Dps was purified via affinity 
chromatography through a His-6 tag by means of a GE 5 ml Histrap FF 
Column using wash buffer (30 mM NaH2PO4, 300 mM NaCl, 40 mM 
Imidazole, pH 7.6). The protein was eluted using elution buffer (30 mM 
NaHPO4, 300 mM NaCl, 500 mM Imidazole, pH 7.6) and then digested with 
enterokinase (NEB, 2 μg/ml) to remove the affinity tag.  The digestion reaction 
was followed by a second Histrap (GE, Histrap FF, 5 ml, (wash buffer-40 mM 
Imidazole, 50 mM NaH2PO4, 300 mM NaCl, pH 7.4), (elution buffer-500 mM 
  
Imidazole, 50 mM NaH2PO4, 300 mM NaCl, pH 7.4)) to remove the tag from 
solution. The protein solutions were further purified by gel filtration 
chromatography (GE Hiload 16/60 Superdex with running buffer (50 mM 
Tris.HCl, 50 mM NaCl, pH 7.8.)). The degree of purification was assessed 
with SDS PAGE (see Fig. S1) and SEC (see Fig. S6A).  
The design for DpsPAGCC, was established in previously published 
work.41 The gene was transferred from pET-32b to pET-46 to reduce the size 
of the affinity tag. The construct was amplified from the pET-32b plasmid with 
primers providing ligation independent cloning (LIC) sites (Figure S4). The 
PCR solution included Pfu reaction buffer (Promega, 5 µl of 10x), dNTP mix 
(Fermentas, 2 µl of a solution containing dATP, dTTP, dGTP, and dCTP at 2 
mM each), forward and reverse primers (400 ng each, Integrated DNA 
technologies, see Figure S4 for primer sequences), the template (100 ng) and 
Pfu polymerase (Promega, 2 µl of 2.5 U/ µl) in 50 μl total volume and was 
subjected to an initial melting step (95 °C for 30 s), followed by 30 cycles of 
amplification (95 °C for 30 s, 55 °C for 45 s and 72 °C for 1 min) followed by 
72 °C for 7 min. The resulting PCR product was isolated by gel purification 
(Qiagen). The PCR product was then treated with T4 polymerase to create 
complementary overhangs (NEB buffer 2, 2 µl of 10x buffer), dATP (NEB, 2 µl 
of 25 mM), DTT (Sigma, 1 µl of 100 mM), BSA (NEB, 0.2 µl of 100x), PCR 
product (0.3 pmol) and T4 DNA polymerase (NEB, 0.6 µl of 10 U/µl) in a total 
volume of 20 µl, 30 min, 22 °C). The insert was annealed to the opened 
plasmid (0.5 µl of plasmid solution (50 ng/µl)) by incubating (room 
temperature, 30 min) followed by a second incubation with EDTA (room 
temperature, 30 min, 1 µl of 100 mM). The constructs (2.5 µl) were 
transformed (XL-1 Blue, Novagen) and the resulting colonies were assessed 
by colony PCR. A solution of Gotaq reaction buffer (5 µl of 5x), dNTP mix 
(Promega, 2 µl of a solution containing dATP, dTTP, dGTP, and dCTP at 2 
mM each), T7 promoter and terminator primers (150 ng each, Eurofins MWG), 
Gotaq DNA polymerase (Promega, 0.25 µl of 5 U/ µl), colony suspension (10 
µl of a 50 µl total colony suspension in deionised water) and deionised water 
(5 μl), was subjected to an initial melting step (95 °C for 10 min) followed by 
amplification 30 cycles (95 °C for 30 s, 59 °C for 30 s and 72 °C for 30 s 
followed by 72 °C for 7 min) Clones demonstrating a PCR product of the 
predicted size were subjected to miniprep (Promega) and the resulting 
purified plasmid was sequenced (see Fig. S5 for full sequence).  
The vector containing DpsPAGCC was transformed into Rosetta E.coli 
cells (Novagen) and plated on LB agar plates (50 μl/ml of carbenicillin and 34 
μl/ml of chloramphenicol). Selected colonies were then grown in LB (5 ml, 37 
°C, overnight) as a pre-culture which was added to LB (500 ml) and grown (37 
°C) until an O.D600 of 0.6. Protein expression was then induced by the 
addition of IPTG (250 µl of a 1 M stock) and the cultures were further 
incubated (3 h, 30 °C). The cells were isolated by centrifugation (4,000 rpm, 
20 min, 4 °C). The cell pellet was resuspended in lysis buffer (50 mM NaH-
2PO4, 300 mM NaCl, 40 mM Imidazole, 1 mM EDTA, pH 8). Cellytic (10x, 
Sigma) was added and the solution was incubated (20 min, on ice) and then 
sonicated (Misonix, ultrasonic cell distruptor, and pulsed for for 5 min (5 s on, 
5 s off)). The protein solution was clarified by centrifugation (15,000 rpm, 45 
min at 4 °C) and then filtered (Sartorius, 0.2 μm). DpsPAGCC was purified via 
affinity purification (GE, Histrap FF, 5 ml, (wash buffer-40 mM Imidazole, 50 
  
mM NaH2PO4, 300 mM NaCl, pH 7.4), (elution buffer-500 mM Imidazole, 50 
mM NaH2PO4, 300 mM NaCl, pH 7.4)), followed by gel filtration 
chromatography (GE Hiload 16/60 Superdex, running buffer- FlAsH buffer 
(100 mM Tris.HCl, 100 mM NaCl, 1 mM EDTA, pH 7.8). The degree of 
purification was assessed with SDS PAGE (see Figure  S2) and SEC (see 
Figure S3). 
 
5.2 Protein cage stability screen of DpsPAGCC with reagents for gold 
nanocage formation 
 
A medium throughput assay based on our previous work41,40 was 
performed using DpsPAGCC. The protein (final concentration 0.1 mg/ml) was 
incubated in FlAsH buffer (100 mM Tris.HCl, 100 mM NaCl, 1 mM EDTA, pH 
7.8) in the presence of the various reagents in a total volume of 200 μl. Each 
reagent (chloroauric acid, sodium borohydride, sodium cyanoborohydride, 
trisodium citrate and ascorbic acid, all sourced from Sigma) were solubilised 
in either water (followed by no pH adjustment) or FlAsH buffer (followed by pH 
adjustment to 7.8 if necessary). The reagents were added to each well with 
varying final concentrations (0.01 M, 0.05 M, 0.1 M, 0.2 M, 0.5 M and 1 M) 
and the solutions were incubated (1 h, room temperature). To these solutions 
TCEP (Sigma, final concentration of 3.5 mM in FlAsH buffer), EDT (Sigma, 
final concentration of 1 mM in FlAsH buffer) and 2-ME (Sigma, final 
concentration of 1 mM in FlAsH buffer) were added, the resulting solutions 
were incubated (2 h, room temperature), after which FlAsH-EDT2 (Invitrogen, 
final concentration of 0.1 μM, 2 h, room temperature) was added and the 
resulting solutions were further incubated. Each sample was prepared directly 
in a black Corning 96 well plate which was scanned in a PerkinElmer Envision 
2101 Multilabel plate reader (Ex filter 485 nm bandwidth 14 nm, Em filter 535 
nm bandwidth 25 nm). Each sample was prepared three times separately and 
each plate was reread three times and averaged. 
 
5.3 Conditions for the formation of nanoparticles inside HsFn from Fan 
et al. (2010)13 applied to Dps (Conditions used for Figures 1C-top and S6B) 
 
Following the original method for the generation of nanoparticles in 
HsFn as previously described,13 the initial gold source (22.6 μl of 0.1 M 
HAuCl4 solution in water) was added to the protein, Dps, (1 ml of a 1 mg/ml, 
in phosphate buffer, 50 mM Na2PO4, 100 mM NaCl, pH 7). This solution was 
incubated (3 h, room temp) and then the sample was desalted (GE 5 ml 
HiTrap desalting column, into Tris buffer (50 mM Tris, 50 mM NaCl, pH 7.8)) 
to remove any un-encapsulated gold. The protein was collected (1 ml) and the 
first reducing agent was added (20 μl of 0.1 M NaBH4 solubilised in water) 
and the resulting solution was incubated (3 h, room temp) with shaking. After 
initial reduction, a second gold solution was added (10 μl of a 0.1 M HAuCl4 
solubilised in water) followed by a second reducing agent (30 μl of  0.1 M 
ascorbic acid solubilised in water) followed by incubation (overnight, room 
temp). Samples were centrifuged (10 min, 10,000 rpm) before SEC 
characterisation. 
  
 
5.4 Conditions optimized in this report through the medium throughput 
assay applied to Dps (Conditions used for Fig. 1C-bottom and Fig. S6C) 
 
 The first gold source (100 µl of 0.05 mM HAuCl4 in Tris buffer (50 mM 
Tris.HCl, pH 7.8)) was added to 1 ml of 1 mg/ml of Dps (in 50 mM Tris.HCl, 
pH 7.8), and the solution was incubated (2 h, room temp). This sample was 
desalted using a GE 5 ml HiTrap desalting column and Tris buffer (50 mM 
Tris, 50 mM NaCl, pH 7.8) to remove any un-encapsulated gold. The protein 
peak was collected (1 ml) and the first reducing agent was added (100 μl of 
0.1 M NaCNBH3 in Tris buffer (50 mM Tris.HCl, pH 7.8)) and the solution was 
incubated (3 h, room temp) with shaking. After incubation, a second gold 
solution was added (100 µl of 0.05 mM HAuCl4 in Tris buffer (50 mM Tris.HCl, 
pH 7.8)), as well as a second reducing agent (50 µl of 0.1 mM ascorbic acid in 
Tris buffer (50 mM Tris.HCl, pH 7.8)) and this was incubated (overnight, room 
temperature) before SEC characterisation. 
 
5.5 Size exclusion chromatography (SEC) 
 
The samples (0.5 mg/ml) in Tris buffer (50 mM Tris.HCl, 50 mM NaCl, 
pH 7.8) were injected (0.5 ml) on to a size exclusion column (GE Superdex 
200 10/300 GL) at 0.5 ml/min. All samples were analysed for both protein 
stability (280 nm) and associated nanoparticle formation (520 nm).  
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